SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2026)
SAB Biotherapeutics (SABS) posted Cash from Operations of 14271130.0 for Q1 2026, up 14.93% on a QoQ basis from 16776327.0 in Q4 2025, and down 83.03% year-over-year from 84088839.33 in Q1 2025.
SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 14271130.0 for Q1 2026.
- Quarterly Cash from Operations fell 83.03% year-over-year to 14271130.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51249024.0 (down 63.53% YoY) and the FY2025 annual result came in at 44775111.0, down 30.57% from the prior year.
- Cash from Operations was 14271130.0 for Q1 2026 at SAB Biotherapeutics, up from 16776327.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1555024.0 in Q4 2022 and bottomed at 16776327.0 in Q4 2025.
- A 5-year average of 8348068.59 and a median of 7797217.0 in 2025 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 83.16% in 2023, while the deepest fall reached 764.73% in 2023.
- SAB Biotherapeutics' Cash from Operations stood at 1555024.0 in 2022, then slumped by 764.73% to 13446717.0 in 2023, then gained by 29.11% to 9532188.0 in 2024, then plunged by 76.0% to 16776327.0 in 2025, then gained by 14.93% to 14271130.0 in 2026.
- Business Quant data shows SABS's Cash from Operations at 14271130.0 in Q1 2026, 16776327.0 in Q4 2025, and 13050023.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -14.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.27 Mn |
| Mar 31, 2026 | -14.27 Mn |
| Dec 31, 2025 | -16.78 Mn |
| Dec 31, 2025 | -16.78 Mn |
| Sep 30, 2025 | -13.05 Mn |
| Sep 30, 2025 | -13.05 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.80 Mn |
| Mar 31, 2025 | -7.80 Mn |
| Dec 31, 2024 | -9.53 Mn |
| Dec 31, 2024 | -9.53 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Sep 30, 2024 | -6.29 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -10.75 Mn |
| Mar 31, 2024 | -10.75 Mn |
| Dec 31, 2023 | -13.45 Mn |
| Dec 31, 2023 | -13.45 Mn |